Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Deun KV, Smilde AK, Berg RAVD, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, Most RV, Didierlaurent AM. Coccia M, et al. Among authors: bourguignon p. NPJ Vaccines. 2017 Sep 8;2:25. doi: 10.1038/s41541-017-0027-3. eCollection 2017. NPJ Vaccines. 2017. PMID: 29263880 Free PMC article.
Erratum: Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Van Deun K, Smilde AK, van den Berg RA, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, van der Most R, Didierlaurent AM. Coccia M, et al. Among authors: bourguignon p. NPJ Vaccines. 2018 Mar 21;3:13. doi: 10.1038/s41541-018-0047-7. eCollection 2018. NPJ Vaccines. 2018. PMID: 29582861 Free PMC article.
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants.
Budroni S, Buricchi F, Cavallone A, Bourguignon P, Caubet M, Dewar V, D'Oro U, Finco O, Garçon N, El Idrissi M, Janssens M, Leroux-Roels G, Marchant A, Schwarz T, Van Damme P, Volpini G, van der Most R, Didierlaurent AM, Burny W. Budroni S, et al. Among authors: bourguignon p. NPJ Vaccines. 2021 May 21;6(1):78. doi: 10.1038/s41541-021-00337-0. NPJ Vaccines. 2021. PMID: 34021167 Free PMC article.
Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.
Leroux-Roels G, Bourguignon P, Willekens J, Janssens M, Clement F, Didierlaurent AM, Fissette L, Roman F, Boutriau D. Leroux-Roels G, et al. Among authors: bourguignon p. Clin Vaccine Immunol. 2014 Mar;21(3):302-11. doi: 10.1128/CVI.00617-13. Epub 2014 Jan 3. Clin Vaccine Immunol. 2014. PMID: 24391139 Free PMC article. Clinical Trial.
An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, Collard A, Demoitié MA, Voss G, Leroux-Roels G, McNally L. Van Braeckel E, et al. Among authors: bourguignon p. Clin Infect Dis. 2011 Feb 15;52(4):522-31. doi: 10.1093/cid/ciq160. Epub 2011 Jan 5. Clin Infect Dis. 2011. PMID: 21208909 Free PMC article. Clinical Trial.
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
Omosa-Manyonyi G, Mpendo J, Ruzagira E, Kilembe W, Chomba E, Roman F, Bourguignon P, Koutsoukos M, Collard A, Voss G, Laufer D, Stevens G, Hayes P, Clark L, Cormier E, Dally L, Barin B, Ackland J, Syvertsen K, Zachariah D, Anas K, Sayeed E, Lombardo A, Gilmour J, Cox J, Fast P, Priddy F. Omosa-Manyonyi G, et al. Among authors: bourguignon p. PLoS One. 2015 May 11;10(5):e0125954. doi: 10.1371/journal.pone.0125954. eCollection 2015. PLoS One. 2015. PMID: 25961283 Free PMC article. Clinical Trial.
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
Leroux-Roels I, Koutsoukos M, Clement F, Steyaert S, Janssens M, Bourguignon P, Cohen K, Altfeld M, Vandepapelière P, Pedneault L, McNally L, Leroux-Roels G, Voss G. Leroux-Roels I, et al. Among authors: bourguignon p. Vaccine. 2010 Oct 8;28(43):7016-24. doi: 10.1016/j.vaccine.2010.08.035. Epub 2010 Aug 20. Vaccine. 2010. PMID: 20728522 Clinical Trial.
33 results